References for “Identifying Optimal Hematocrit Levels”

1. Murray CD. The physiological principle of minimum work. II. Oxygen exchange in capillaries. Proc. Natl. Acad. Sci. U.S.A. (1926; 12:299-304).

2. Murray JF, Gold P, Johnson BL Jr. The circulatory effects of hematocrit variations in normovolemic and hypervolemic dogs. J. Clin. Invest. (1963; 42:1150-1159).

3. Bevan J.A, Kaley G, Rubanyi GM. Flow-dependent regulation of vascular function. (1995) Oxford University Press, New York.

4. Birchard GF, Tenney SM. Relationship between blood-oxygen affinity and blood volume. Respir. Physiol. (1995; 83:365-374).

5. Cabrales P, Tsai AG, Intaglietta M. Balance between vasoconstriction and enhanced oxygen delivery. Transfusion. (2008; Jun 27).

6. National Kidney Foundation-Dialysis Outcomes Quality Initiative. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis (1997; 30: S192-S240).

7. Churchill DN, Muirhead N, Goldstein M et al. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Clin Nephrol. (1995; 43: 184-188).

8. Collins AJ, Li S, Ebben J et al. Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 2000; 36: 282-293.

9. Ma J, Ebben J, Xia H et al. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. (1999; 10: 610-619).

10. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidneydisease and anemia. N Engl J Med. (2006; 355:2071-2084).

11. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. (2006; 355: 2085-2098).

12. Ishani A, Solid CA, Weinhandl ED et al. Association Between Number Of Months Below K/DOQI Haemoglobin Target And Risk Of Hospitalization And Death Nephrol Dial Transplant. (2008; 23, 5:1682-1689).

13. Silver M, Corwin MJ, Bazan A, et al. .Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.Crit Care Med. (2006 Sep; 34, 9:2310-6).

14. Kristiansson M, Soop M, Saraste L et al. Cytokines in stored red blood cell concentrates: promoters of systemic inflammation and simulators of acute transfusion reactions? Acta Anaesthesiol Scand. (1996; 40: 496-501).

15. Vamvakas, EC, Blajchman, MA Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood. 2001;1; 97,1180-1195

16. Taylor RW, Manganaro L, O’Brien J et al. Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit Care Med. (2002; 30: 2249-2254).

17. Roberts GH. Transfusion-related acute lung injury (TRALI). Clin Lab Sci. (2004; 17: 133-135).

18. Shorr AF, Duh MS, Kelly KM et al. Red blood cell transfusion and ventilator-associated pneumonia: a potential link? Crit Care Med. (2004; 32: 666-674).

19. Cohn SM. Blood substitutes in surgery. Surgery. (2000;127: 599-602).

20. Corwin HL, Gettinger A, Pearl RG et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA. (2002; 288: 2827-2835).